• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用干细胞和纳米生物技术模板开发生物人工心肌。

Development of bioartificial myocardium using stem cells and nanobiotechnology templates.

机构信息

Department of Cardiovascular Surgery and Laboratory of Biosurgical Research, Pompidou Hospital, University Paris Descartes, 20 rue Leblanc, 75015 Paris, France.

出版信息

Cardiol Res Pract. 2010 Dec 29;2011:806795. doi: 10.4061/2011/806795.

DOI:10.4061/2011/806795
PMID:21253535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3021848/
Abstract

Cell-based regenerative therapy is undergoing experimental and clinical trials in cardiology, in order to limit the consequences of decreased contractile function and compliance of damaged ventricles following myocardial infarction. Over 1000 patients have been treated worldwide with cell-based procedures for myocardial regeneration. Cellular cardiomyoplasty seems to reduce the size and fibrosis of infarct scars, limit adverse postischemic remodelling, and improve diastolic function. The development of a bioartificial myocardium is a new challenge; in this approach, tissue-engineered procedures are associated with cell therapy. Organ decellularization for bioscaffolds fabrication is a new investigated concept. Nanomaterials are emerging as the main candidates to ensure the achievement of a proper instructive cellular niche with good drug release/administration properties. Investigating the electrophysiological properties of bioartificial myocardium is the challenging objective of future research, associating a multielectrode network to provide electrical stimulation could improve the coupling of grafted cells and scaffolds with host cardiomyocytes. In summary, until now stem cell transplantation has not achieved clear hemodynamic benefits for myocardial diseases. Supported by relevant scientific background, the development of myocardial tissue engineering may constitute a new avenue and hope for the treatment of myocardial diseases.

摘要

基于细胞的再生疗法正在心脏病学领域进行实验和临床试验,以限制心肌梗死后收缩功能下降和受损心室顺应性的后果。全球已有超过 1000 名患者接受了基于细胞的心肌再生治疗。细胞心肌成形术似乎可以减小梗塞疤痕的大小和纤维化程度,限制缺血后不良重构,并改善舒张功能。生物人工心脏的发展是一个新的挑战;在这种方法中,组织工程程序与细胞治疗相结合。用于生物支架制造的器官脱细胞化是一个新的研究概念。纳米材料作为确保获得具有良好药物释放/给药特性的适当指导细胞生态位的主要候选材料而出现。研究生物人工心脏的电生理特性是未来研究的挑战性目标,通过多电极网络提供电刺激可以改善移植细胞和支架与宿主心肌细胞的偶联。总之,到目前为止,干细胞移植并没有为心脏病带来明显的血流动力学益处。在相关科学背景的支持下,心肌组织工程的发展可能为治疗心脏病提供新的途径和希望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d84/3021848/b897d7dd928c/CRP2011-806795.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d84/3021848/b897d7dd928c/CRP2011-806795.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d84/3021848/b897d7dd928c/CRP2011-806795.001.jpg

相似文献

1
Development of bioartificial myocardium using stem cells and nanobiotechnology templates.利用干细胞和纳米生物技术模板开发生物人工心肌。
Cardiol Res Pract. 2010 Dec 29;2011:806795. doi: 10.4061/2011/806795.
2
Cellular cardiac regenerative therapy in which patients?针对哪些患者的细胞心脏再生疗法?
Expert Rev Cardiovasc Ther. 2009 Aug;7(8):911-9. doi: 10.1586/erc.09.84.
3
Cell based approaches for myocardial regeneration and artificial myocardium.基于细胞的心肌再生和人工心肌方法。
Curr Stem Cell Res Ther. 2007 May;2(2):121-7. doi: 10.2174/157488807780599239.
4
Myocardial assistance by grafting a new bioartificial upgraded myocardium (MAGNUM clinical trial): one year follow-up.通过移植新型生物人工升级心肌进行心肌辅助(MAGNUM临床试验):一年随访
Cell Transplant. 2007;16(9):927-34. doi: 10.3727/096368907783338217.
5
Association between a cell-seeded collagen matrix and cellular cardiomyoplasty for myocardial support and regeneration.细胞接种胶原基质与细胞心肌成形术用于心肌支持和再生之间的关联。
Tissue Eng. 2007 Nov;13(11):2681-7. doi: 10.1089/ten.2006.0447.
6
Cellular cardiomyoplasty: clinical application.细胞心肌成形术:临床应用
Ann Thorac Surg. 2004 Mar;77(3):1121-30. doi: 10.1016/j.athoracsur.2003.09.081.
7
Myocardial Assistance by Grafting a New Bioartificial Upgraded Myocardium (MAGNUM trial): clinical feasibility study.通过移植新型生物人工升级心肌实现心肌辅助(MAGNUM试验):临床可行性研究
Ann Thorac Surg. 2008 Mar;85(3):901-8. doi: 10.1016/j.athoracsur.2007.10.052.
8
Update: Innovation in cardiology (IV). Cardiac tissue engineering and the bioartificial heart.更新:心脏病学中的创新(四)。心脏组织工程与生物人工心脏。
Rev Esp Cardiol (Engl Ed). 2013 May;66(5):391-9. doi: 10.1016/j.rec.2012.11.012. Epub 2013 Mar 6.
9
Building a Total Bioartificial Heart: Harnessing Nature to Overcome the Current Hurdles.构建全生物人工心脏:利用自然力量克服当前障碍
Artif Organs. 2018 Oct;42(10):970-982. doi: 10.1111/aor.13336. Epub 2018 Oct 16.
10
Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy.细胞心肌成形术和心脏组织工程学用于心肌治疗。
Adv Drug Deliv Rev. 2010 Jun 15;62(7-8):784-97. doi: 10.1016/j.addr.2010.03.001. Epub 2010 Mar 6.

引用本文的文献

1
Mesenchymal stem cell therapy in nonhematopoietic diseases.间充质干细胞疗法在非造血系统疾病中的应用
Stem Cells Int. 2015;2015:676903. doi: 10.1155/2015/676903. Epub 2015 Mar 1.
2
Development of bioartificial myocardium by electrostimulation of 3D collagen scaffolds seeded with stem cells.通过对接种干细胞的三维胶原蛋白支架进行电刺激来开发生物人工心肌。
Heart Int. 2012 Jun 5;7(2):e14. doi: 10.4081/hi.2012.e14. Epub 2012 Sep 18.
3
The acellular myocardial flap: a novel extracellular matrix scaffold enriched with patent microvascular networks and biocompatible cell niches.

本文引用的文献

1
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.心率作为慢性心力衰竭的危险因素(SHIFT):一项随机安慰剂对照试验中心率与结局的关系。
Lancet. 2010 Sep 11;376(9744):886-94. doi: 10.1016/S0140-6736(10)61259-7.
2
Bioengineering endothelialized neo-corneas using donor-derived corneal endothelial cells and decellularized corneal stroma.利用供体来源的角膜内皮细胞和去细胞化的角膜基质生物工程化内皮neo 角膜。
Biomaterials. 2010 Sep;31(26):6738-45. doi: 10.1016/j.biomaterials.2010.05.020. Epub 2010 Jun 11.
3
Mesothelial cells vs. skeletal myoblasts for myocardial infarction.
去细胞心肌瓣:一种富含专利微血管网络和生物相容细胞龛的新型细胞外基质支架。
Tissue Eng Part C Methods. 2013 Jul;19(7):518-30. doi: 10.1089/ten.TEC.2012.0536. Epub 2013 Jan 16.
4
Nano-regenerative medicine towards clinical outcome of stem cell and tissue engineering in humans.纳米再生医学在人类干细胞和组织工程中的临床转归。
J Cell Mol Med. 2012 Sep;16(9):1991-2000. doi: 10.1111/j.1582-4934.2012.01534.x.
5
Biomaterial strategies for alleviation of myocardial infarction.用于缓解心肌梗死的生物材料策略。
J R Soc Interface. 2012 Jan 7;9(66):1-19. doi: 10.1098/rsif.2011.0301. Epub 2011 Sep 7.
间皮细胞与骨骼肌成肌细胞用于心肌梗死治疗的比较
Asian Cardiovasc Thorac Ann. 2010 Feb;18(2):153-60. doi: 10.1177/0218492310361793.
4
Predifferentiated adult stem cells and matrices for cardiac cell therapy.用于心脏细胞治疗的预分化成体干细胞和基质
Asian Cardiovasc Thorac Ann. 2010 Feb;18(1):79-87. doi: 10.1177/0218492309355836.
5
Regenerative medicine strategies for treatment of neurogenic bladder.治疗神经源性膀胱的再生医学策略。
Therapy. 2009;6(2):177-184. doi: 10.2217/14750708.6.2.177.
6
Whole organ decellularization - a tool for bioscaffold fabrication and organ bioengineering.全器官去细胞化——一种用于生物支架制造和器官生物工程的工具。
Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:6526-9. doi: 10.1109/IEMBS.2009.5333145.
7
Repeated implantation of skeletal myoblast in a swine model of chronic myocardial infarction.骨骼肌母细胞在慢性心肌梗死猪模型中的重复植入。
Eur Heart J. 2010 Apr;31(8):1013-21. doi: 10.1093/eurheartj/ehp342. Epub 2009 Aug 22.
8
Myocardial tissue engineering: the quest for the ideal myocardial substitute.心肌组织工程:对理想心肌替代物的探索。
Expert Rev Cardiovasc Ther. 2009 Aug;7(8):921-8. doi: 10.1586/erc.09.81.
9
Cellular cardiac regenerative therapy in which patients?针对哪些患者的细胞心脏再生疗法?
Expert Rev Cardiovasc Ther. 2009 Aug;7(8):911-9. doi: 10.1586/erc.09.84.
10
Association of electrostimulation with cell transplantation in ischemic heart disease.电刺激与细胞移植在缺血性心脏病中的联合应用。
J Thorac Cardiovasc Surg. 2009 Oct;138(4):994-1001. doi: 10.1016/j.jtcvs.2009.02.025. Epub 2009 Apr 9.